Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 response rates.

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Please provide your email address to receive an email when new articles are posted on . Among targeted small-molecule drugs, deucravacitinib had the best efficacy and safety in SLE. Dose and course of ...

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...

In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.